



## DERMATOLOGY UPDATE 2004 • SCHEDULE OF EVENTS

*Thursday, October 14, 2004 – Stanley Park Ballroom*

Time	Topic
9:30 – 11:00	Case Studies in Onychomycosis  Non typical onychomycosis cases will be presented. Interaction with the audience on treatment approaches will be facilitated through touch pads.
2:00 – 3:30	Shaping the Management of Psoriasis – Achieving Long-Term Control
2:00	Introduction: Long-term Control – An Unmet Need in Psoriasis <i>Dr. Vincent Ho</i>
2:10	Efalizumab – An Innovative Biological that Combines Safety and Efficacy <i>Kim Papp</i>
2:35	Practical Experience Using Efalizumab <i>Alan Menter</i>
2:55	Integrating Biologic Agents into the Management of Moderate to Severe Psoriasis – A Canadian Expert Panel Consensus <i>Richard Langley</i>
3:15	Conclusions; Q&A Session <i>Vincent Ho</i>



*Thursday, October 14, 2004 – Stanley Park Ballroom*

Time	Topic
4:00 – 5:00	<p>Novel Findings in Atopic Dermatitis: How To Maximize Treatments</p> <p>Atopic dermatitis (AD), a chronic inflammatory, severely itchy skin disease, with an increasing global prevalence affecting at least 10 - 20 % of children but which may persist into adulthood, is believed to be the first step in the "atopic march" resulting in asthma and allergic rhinitis.</p> <p>The phenotype of the disease is viewed as the result of the interaction between environmental factors, defective skin barrier function and susceptibility genes resulting in immunological and distal neurological abnormalities.</p> <p>The enormous progress in our understanding of the complex pathophysiology of AD, as well as our better knowledge of the structure of the barrier function of the skin and of the role of patient therapeutic education, have ultimately allowed the development of novel therapeutic strategies.</p>
4:00	<p>Opening <i>Dr. Danielle Marcoux</i></p>
4:05	<p>Immunological Aspects of Atopic Dermatitis: What do we know? <i>Dr. Thomas Luger</i></p>
4:35	<p>Emollients and Barrier Function in Atopic Dermatitis <i>Dr. Andre Rougier</i></p>
4:55	<p>Patients Therapeutic Education: the Role and Benefits of School of Atopy <i>Dr. Danielle Marcoux</i></p>
5:20	<p>Question and Answer Panel</p>



*Friday, October 15, 2004 – Bayshore Ballroom DEF*

**Time            Topic**

---

9:30 – 11:00    Clinical Advances in the Use of Imiquimod

Aldara for AK: Clinical Approaches

*Dr. Stuart Salasche*

Immune Response Modifiers - An Innovative Approach to NMSC

*Prof. Eggert Stockfleth*

11:30 – 1:30    Advancing the Treatment of Psoriasis and Psoriatic Arthritis  
with Biologic Therapies: Practical Application of Using TNF  
Antagonists (*Lunch provided*)

By attending this symposium, participants will be able to:

- Understand the immunologic effect of targeting tumor necrosis factor (TNF) alpha in psoriatic disease
- Interpret recent clinical trial data for TNF antagonists in the treatment of psoriatic arthritis and psoriasis
- Distinguish between TNF antagonists based on safety and mechanism of action
- Rationalize the need to incorporate biologic therapy for psoriatic disease into dermatology practice
- Describe strategies for optimizing response to TNF antagonists in clinical practice

11:30    Introduction, Learning Objectives

*Yves P. Poulin, MD, FRCPC*

11:40    Biologic Treatment of Psoriatic Arthritis & Psoriasis

*Kim A. Papp, MD, PhD, FRCPC*

12:05    Interpreting the Safety Experience with TNF Antagonists

*Richard G.B. Langley, MD, FRCPC*

12:30    Practical Approaches and Considerations for Using TNF  
Antagonists in Clinical Practice: US Experience

*Bruce Strober, MD, PhD*

13:10    Close, Q&A – *Yves Poulin, MD, FRCPC*

13:30    Adjourn

2:00 – 3:30    Redefining Efficacy in Psoriasis



*Saturday, October 16, 2004 – Bayshore Ballroom DEF*

	<b>Time</b>	<b>Topic</b>	<b>Speaker</b>	
<b>SESSION 1</b>	7:00 – 8:00	Breakfast		
	8:00 – 8:05	Opening Remarks	Dr. Harvey Lui	
	Chair: Dr. Harvey Lui	8:05 – 8:20	Review of Drugs for the Treatment of of Skin Disease	Dr. Stuart Maddin
		8:20 – 8:35	Treating Pemphigus Vulgaris with IVIG: Assessing the Strength of Evidence	Dr. Neil Shear
	8:35 – 8:50	Valcyclovir in the Treatment and Prevention of Herpes Infections	Dr. Stephen Tying	
	8:50 – 9:05	Immune Response Modifiers - An Innovative Approach to NMSC	Prof. Eggert Stockfleth	
	9:05 – 9:20	Eczema/Corticosteroids	Dr. John Berth-Jones	
	9:20 – 9:35	Anti-psoriatics / biologics	Dr. Alan Menter	
	9:35 – 9:55	<i>Panel and Questions</i>		
	9:55 – 10:15	<i>Coffee Break and Poster Exhibits</i>		
<b>SESSION 2</b>	10:15 – 10:30	Current Management of Atopic Dermatitis	Dr. Thomas Luger	
	Chair: Dr. Jan Dutz	10:30 – 10:45	Role of Staphylococcus Aureus in Atopic Dermatitis	Dr. Donald Leung
		10:45 – 11:00	Psoriasis / Retinoids	Dr. Kim Papp
	11:00 – 11:15	TNF Antagonists in the Treatment of Psoriasis and Psoriatic Arthritis: Case Studies	Dr. Bruce Strober	
	11:15 – 11:30	A Canadian Expert Panel Consensus – Integrating Biologic Agents in the Management of Moderate to Severe Psoriasis	Dr. Richard Langley	
	11:30 – 11:45	Pimecrolimus for Atopic Dermatitis and Where Do We Go From Here?	Prof. Klaus Wolff	
	11:45 – 12:05	<i>Panel and Questions</i>		



*Saturday, October 16, 2004 – Bayshore Ballroom DEF*

	<b>Time</b>		<b>Speaker</b>
<b>RAPID FIRE LUNCH</b>	12:05 – 2:00	<i>(Bayshore Ballroom ABC)</i>	
	1.	CellCept®: A New and Emerging Therapy	Dr. Regine Mydlarski
<b>Chair:</b>	2.	The Effect of Periocular Hemangiomas on Visual Development in Children	Dr. Bryce Cowan
	3.	Treating Mycosis Fungoides: What, How, Why?	Dr. Marni Wiseman
	4.	A Brief Review of Eczema Management	Dr. Jim Bergman
<b>SESSION 3</b>	2:00 – 2:15	Genetic Applications in Dermatology	Mr. Greg Hines
<b>Chair:</b>	2:15 – 2:30	Development of Immune Response Modifiers	Dr. Richard Miller
<b>Dr. Jerry Shapiro</b>	2:30 – 2:55	Photoaging: Update and Treatment	Dr. Sheldon Pinnell
	2:55 – 3:10	<i>Panel and Questions</i>	
	3:10 – 3:30	<i>Coffee Break and Poster Exhibits</i>	
<b>SESSION 4</b>	3:30 – 3:45	Acne – Quality of Life	Dr. Andrew Finlay
	3:45 – 4:00	PDT and the Sebaceous Gland: Preclinical Results	Dr. David Hunt
<b>Chair:</b>	4:00 – 4:15	Topical Retinoids and their Effect On Inflammatory Mediators in Acne	Dr. Sewon Kang
<b>Dr. Neil Shear</b>	4:15 – 4:30	An Update on the Management of Onychomycosis	Dr. Aditya Gupta
	4:30 – 4:20	<i>Panel and Questions</i>	
	4:20 – 4:50	Acute Skin Failure	
		Canadian Consensus Consult Guidelines Treatment of Acute Skin Failure	Dr. Ron Vender Dr. Ian Landells and Dr. Kevin Smith
		Who's Who in Canadian Dermatology	Dr. Chuck Lynde
		The Father of All Azoles	Dr. Geert Cauwenbergh
		Session Summary	Dr. Richard Thomas
	4:50 – 5:00	Closing Comments	Dr. Stuart Maddin



---

**GALA DINNER**

7:30 – 8:00 Reception (*Bayshore Ballroom Foyer*)

8:00 – 11:00 Dinner (*Bayshore Ballroom ABC*)

Please join us in celebrating Dermatology Update's 20<sup>th</sup> Anniversary.  
Attire is business formal or black tie.

Pre registration is required (tickets will be on sale until Thursday, October 14<sup>th</sup> as all seats will be pre-assigned).